Shares of Arvinas Inc (NASDAQ:ARVN) have been given an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have given a strong buy rating to the company. Arvinas’ rating score has declined by 67% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus price objective of $27.00 for the company and are forecasting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given Arvinas an industry rank of 75 out of 256 based on the ratings given to its competitors.
Several research firms have weighed in on ARVN. Piper Jaffray Companies upped their target price on Arvinas from $23.00 to $32.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. Evercore ISI began coverage on Arvinas in a research note on Thursday, April 11th. They set an “outperform” rating for the company. Zacks Investment Research cut Arvinas from a “hold” rating to a “sell” rating in a research note on Monday, May 27th. Finally, Citigroup cut Arvinas from a “buy” rating to a “neutral” rating and upped their target price for the stock from $21.00 to $22.00 in a research note on Wednesday, June 5th.
Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46). The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $3.50 million. Analysts forecast that Arvinas will post -1.86 EPS for the current year.
In other news, Director Timothy M. Shannon purchased 3,500 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was bought at an average cost of $14.69 per share, for a total transaction of $51,415.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ventures Iii L.P. 5Am sold 190,000 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $19.65, for a total value of $3,733,500.00. The disclosure for this sale can be found here. 31.77% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC lifted its stake in shares of Arvinas by 1.2% in the 4th quarter. Orbimed Advisors LLC now owns 2,678,810 shares of the company’s stock valued at $34,423,000 after acquiring an additional 32,945 shares during the last quarter. Hillhouse Capital Advisors Ltd. bought a new position in shares of Arvinas in the 4th quarter valued at $8,031,000. BlackRock Inc. lifted its stake in shares of Arvinas by 109.2% in the 4th quarter. BlackRock Inc. now owns 545,443 shares of the company’s stock valued at $7,009,000 after acquiring an additional 284,656 shares during the last quarter. Sphera Funds Management LTD. lifted its stake in shares of Arvinas by 12.9% in the 4th quarter. Sphera Funds Management LTD. now owns 271,053 shares of the company’s stock valued at $3,483,000 after acquiring an additional 31,053 shares during the last quarter. Finally, Redmile Group LLC lifted its stake in shares of Arvinas by 10.8% in the 1st quarter. Redmile Group LLC now owns 150,955 shares of the company’s stock valued at $2,228,000 after acquiring an additional 14,655 shares during the last quarter. Institutional investors own 43.00% of the company’s stock.
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.
Recommended Story: What is the market perform rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.